Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

被引：0

作者：

Takeshi Kato

Yoshinori Kagawa

Yasutoshi Kuboki

Makio Gamoh

Yoshito Komatsu

Hirofumi Yasui

Hironaga Satake

Eiji Oki

Hiroaki Tanioka

Masahito Kotaka

Akitaka Makiyama

Tadamichi Denda

Masahiro Goto

Takayuki Yoshino

Kentaro Yamazaki

Junpei Soeda

Kazunori Shibuya

Masaru Iwata

Koji Oba

Kensei Yamaguchi

机构：

[1] National Hospital Organization Osaka National Hospital,Gastroenterological Chemotherapy Department

[2] Kansai Rosai Hospital,Cancer Treatment Center

[3] National Cancer Center Hospital East,undefined

[4] Osaki Citizen Hospital,undefined

[5] Furukawa Honami,undefined

[6] Hokkaido University Hospital,undefined

[7] Shizuoka Cancer Center,undefined

[8] Kobe City Medical Center General Hospital,undefined

[9] Kyushu University,undefined

[10] Okayama Rosai Hospital,undefined

[11] Sano Hospital,undefined

[12] Japan Community Healthcare Organization Kyushu Hospital,undefined

[13] Gifu University Hospital,undefined

[14] Chiba Cancer Center,undefined

[15] Osaka Medical College Hospital,undefined

[16] Takeda Pharmaceutical Company,undefined

[17] University of Tokyo,undefined

[18] Cancer Institute Hospital of Japanese Foundation for Cancer Research,undefined

[19] Kansai Medical University Hospital,undefined

[20] Medical Oncology Kawasaki Medical School,undefined

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Salvage line; Anti-EGFR antibody; Phase 1/2 clinical trial; Oral nucleoside anti-tumour agent; Outcomes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1238 / 1247

页数：9

共 50 条

[41] Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
Pietrantonio, Filippo
Morano, Federica
Corallo, Salvatore
Miceli, Rosalba
Lonardi, Sara
Raimondi, Alessandra
Cremolini, Chiara
Rimassa, Lorenza
Bergamo, Francesca
Sartore-Bianchi, Andrea
Tampellini, Marco
Racca, Patrizia
Clavarezza, Matteo
Berenato, Rosa
Caporale, Marta
Antista, Maria
Niger, Monica
Smiroldo, Valeria
Murialdo, Roberto
Zaniboni, Alberto
Adamo, Vincenzo
Tomasello, Gianluca
Giordano, Monica
Petrelli, Fausto
Longarini, Raffaella
Cinieri, Saverio
Falcone, Alfredo
Zagonel, Vittorina
Di Bartolomeo, Maria
de Braud, Filippo
JAMA ONCOLOGY, 2019, 5 (09) : 1268 - 1275
[42] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
Naoki Takahashi
Satoru Iwasa
Masaru Fukahori
Kazuki Sudo
Yusuke Sasaki
Hirokazu Shoji
Yoshitaka Honma
Natsuko Tsuda Okita
Atsuo Takashima
Tetsuya Hamaguchi
Narikazu Boku
Yasuhiro Shimada
Kazufumi Honda
Tesshi Yamada
Yasuhide Yamada
Cancer Chemotherapy and Pharmacology, 2016, 78 : 567 - 575
[43] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
Takahashi, Naoki
Iwasa, Satoru
Fukahori, Masaru
Sudo, Kazuki
Sasaki, Yusuke
Shoji, Hirokazu
Honma, Yoshitaka
Okita, Natsuko Tsuda
Takashima, Atsuo
Hamaguchi, Tetsuya
Boku, Narikazu
Shimada, Yasuhiro
Honda, Kazufumi
Yamada, Tesshi
Yamada, Yasuhide
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 567 - 575
[44] Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer
Osumi, H.
Shinozaki, E.
Suenaga, M.
Matsusaka, S.
Nakayama, I.
Wakatsuki, T.
Ogura, M.
Ozaka, M.
Takashi, I.
Takahari, D.
Chin, K.
Mizunuma, N.
Yamaguchi, K.
ANNALS OF ONCOLOGY, 2016, 27 : 16 - 16
[45] Phase Ib/II open-label study to evaluate the safety, tolerability, and efficacy of rivoceranib plus trifluridine/tipiracil in patients with previously treated metastatic colorectal cancer
Eng, C.
Park, C. H.
Meng, X.
Jang, S. H.
ANNALS OF ONCOLOGY, 2023, 34 : S453 - S454
[46] Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Alonso, Vicente
Escudero, Pilar
Fernandez-Martos, Carlos
Salud, Antonia
Mendez, Miguel
Gallego, Javier
Rodriguez, Jose-R.
Martin-Richard, Marta
Fernandez-Plana, Julen
Manzano, Hermini
Mendez, Jose-Carlos
Zanui, Monserrat
Falco, Esther
Gil-Raga, Mireia
Rojo, Federico
Cuatrecasas, Miriam
Feliu, Jaime
Garcia-Albeniz, Xabier
Maurel, Joan
NEOPLASIA, 2018, 20 (07): : 678 - 686
[47] Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
Salvatore, Lisa
Bensi, Maria
Vivolo, Raffaella
Zurlo, Ina Valeria
Dell'Aquila, Emanuela
Grande, Roberta
Anghelone, Annunziato
Emiliani, Alessandra
Citarella, Fabrizio
Calegari, Maria Alessandra
Ribelli, Marta
Basso, Michele
Pozzo, Carmelo
Tortora, Giampaolo
FRONTIERS IN ONCOLOGY, 2023, 13
[48] Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Jing Yang
Xinli Guo
Manni Wang
Xuelei Ma
Xiaoyang Ye
Panpan Lin
Scientific Reports, 7
[49] Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Yang, Jing
Guo, Xinli
Wang, Manni
Ma, Xuelei
Ye, Xiaoyang
Lin, Panpan
SCIENTIFIC REPORTS, 2017, 7
[50] Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.
Karthaus, Meinolf
Kretzschmar, Albrecht
Fuxius, Stefan
Knorrenschild, Jorge Riera
Kaiser, Florian
Mahlberg, Rolf
Welslau, Manfred
Pelz, Henning
Heinemann, Volker
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →